Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection

Emerg Infect Dis. 2013 Mar;19(3):416-24. doi: 10.3201/eid1903.120998.

Abstract

High mortality rates have been reported for patients co-infected with extensively drug-resistant tuberculosis (XDR-TB) and HIV, but treatment outcomes have not been reported. We report treatment outcomes for adult XDR TB patients in KwaZulu-Natal Province, South Africa. Initial data were obtained retrospectively, and outcomes were obtained prospectively during 24 months of treatment. A total of 114 XDR TB patients were treated (median 6 drugs, range 3-9 drugs); 82 (73%) were HIV positive and 50 (61%) were receiving antiretroviral therapy. After receiving treatment for 24 months, 48 (42%) of 114 patients died, 25 (22%) were cured or successfully completed treatment, 19 (17%) withdrew from the study, and 22 (19%) showed treatment failure. A higher number of deaths occurred among HIV-positive patients not receiving antiretroviral therapy and among patients who did not show sputum culture conversion. Culture conversion was a major predictor of survival but was poorly predictive (51%) of successful treatment outcome.

Keywords: HIV; South Africa; XDR TB; bacteria; co-infection; extensively drug-resistant tuberculosis; treatment outcomes; tuberculosis and other mycobacteria; viruses.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / therapeutic use*
  • Coinfection / drug therapy*
  • Coinfection / mortality
  • Cycloserine / therapeutic use
  • Drug Therapy, Combination
  • Ethambutol / therapeutic use
  • Ethionamide / therapeutic use
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Extensively Drug-Resistant Tuberculosis / mortality
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / mortality
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Pyrazinamide / therapeutic use
  • Retrospective Studies
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / mortality
  • Young Adult

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Cycloserine
  • Ethionamide